Is your disease uncommon?

Generally, the more common diseases are cheaper to treat, because the burden of development, IP etc. gets spread across more people.

Medications for ubiquitous stuff such as high blood pressure tend to be comparably cheap, unless they are a fresh novelty. And aging is even more widespread than HBP.

> Is your disease uncommon?

Estimated at 2-3% of the world population, so 100M+ people.

So is the treatment something highly unusual?

I am sorry to be prying such information out of you, but things with such a cost label tend to be very high-tech (e.g. tumor-invading lymphocytes etc. that need to be cultivated for each patient separately, which cannot possibly be cheap).

It's a monoclonal antibody.

I suspect it'll look cheap in comparison to life extension treatments.

That's because monoclonal antibodies are targeted to a very specific protein. Polyclonal antibodies which can be used more generally are much cheaper. You're paying for the purity, not the substance.